Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Clément Daigmorte, Daniela Usturoi, Clément Fournier, Frederic Wallyn, Christine Lorut, Valentin Héluain, Julien Mazières, Julien Legodec, Bruno Escarguel, Thomas Egenod, Laurent Cellerin, Nicolas Favrolt, Samy Lachkar, Adrian Crutu, Amandine Briault, Christophe Gut-Gobert, Valerian Bourinet, Juliette Camuset, Perrot Loïc, Pascal Schlossmacher, Michele Porzio, Antoine Luchez, Jean-Michel Vergnon, Marie-Christelle Pajiep Chapda, Pascalin Roy, Hervé Dutau, Nicolas Guibert
BACKGROUND AND OBJECTIVE: Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non-bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB). METHODS: In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022...
April 18, 2024: Respirology: Official Journal of the Asian Pacific Society of Respirology
#2
JOURNAL ARTICLE
Shunsuke Kasai, Etsuko Sato, Chikara Sakaguchi, Yasutsuna Sasaki
Tumor lysis syndrome (TLS) is a fatal complication associated with chemotherapy. We herein report a case of TLS in a 73-year-old woman with metastatic BRAFV600E mutated colon cancer after she received combined treatment with cetuximab and encorafenib. The serum uric acid, urea nitrogen, and creatinine levels were elevated on day four of the first cycle. The fibrin degradation product (FDP) and D-dimer levels were also high. Diuresis and rasburicase were initiated for TLS, and the laboratory data all normalized on day 8...
April 16, 2024: Internal Medicine
#3
Hyunbin D Huh, Hyun Woo Park
Cancer cells metastasize to distant organs by altering their characteristics within the tumor microenvironment (TME) to effectively overcome challenges during the multistep tumorigenesis. Plasticity endows cancer cell with the capacity to shift between different states to invade, disseminate, and seed metastasis. The epithelial-to-mesenchymal transition (EMT) is a cellular program that abrogates cell-cell adhesions by EMT transcription factors (TF) and acquires mesenchymal features during cancer progression...
April 17, 2024: BMB Reports
#4
JOURNAL ARTICLE
Malte Gronewold, Isabel Grote, Stephan Bartels, Henriette Christgen, Leonie D Kandt, Maria Jose Brito, Gàbor Cserni, Maximilian E Daemmrich, Franz Fogt, Burkhard M Helmke, Natalie Ter Hoeve, Corinna Lang-Schwarz, Michael Vieth, Axel Wellmann, Elna Kuehnle, Ulf Kulik, Gesa Riedel, Tanja Reineke-Plaass, Ulrich Lehmann, Thijs Koorman, Patrick Wb Derksen, Hans Kreipe, Matthias Christgen
Invasive lobular carcinoma (ILC) is a special breast cancer type characterized by noncohesive growth and E-cadherin loss. Focal activation of P-cadherin expression in tumor cells that are deficient for E-cadherin occurs in a subset of ILCs. Switching from an E-cadherin deficient to P-cadherin proficient status (EPS) partially restores cell-cell adhesion leading to the formation of cohesive tubular elements. It is unknown what conditions control EPS. Here, we report on EPS in ILC metastases in the large bowel...
March 2024: Journal of Pathology. Clinical Research
#5
Lijuan He, Haiyuan Li, Yunpeng Wang, Weidong Li, Lei Gao, Bo Xu, Jike Hu, Puyi He, Weigao Pu, Guodong Sun, Zhuanfang Wang, Qinying Han, Ben Liu, Hao Chen
Metastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have demonstrated durable clinical efficacy in a variety of solid tumors, their response requires an inflammatory tumor microenvironment. However, microsatellite-stable ( MSS ) colon cancer, which accounts for the majority of colorectal cancers, is a cold tumor that does not respond well to ICIs...
2024: Frontiers in Immunology
#6
JOURNAL ARTICLE
Md Mazharul Islam
No abstract text is available yet for this article.
November 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
#7
JOURNAL ARTICLE
Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakçı, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur, Cemil Bilir, Bülent Karabulut, İrfan Cicin, Erdem Çubukçu, Mustafa Karaca, Melike Ozcelik, Mehmet Artaç, Eda Tanrikulu, Ahmet Alacacioglu, Özgür Açıkgöz, Başak Öven, Çağlayan Geredeli, Timucin Çil, Hakan Harputluoğlu, Umut Kefeli, Oktay Bozkurt, Deniz Tural, Abdullah Sakin, Şuayip Yalçın, Mahmut Gumus
BACKGROUNDS AND OBJECTIVES: Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311). MATERIALS AND METHODS: In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented...
April 13, 2024: Journal of Oncology Pharmacy Practice
#8
JOURNAL ARTICLE
Abdullah Mahmood Ali, Azra Raza
Metastatic cancer is a leading cause of death in cancer patients worldwide. While circulating hybrid cells (CHCs) are implicated in metastatic spread, studies documenting their tissue origin remain sparse, with limited candidate approaches using one-two markers. Utilizing high-throughput single-cell and spatial transcriptomics, we identified tumor hybrid cells (THCs) co-expressing epithelial and macrophage markers and expressing a distinct transcriptome. Rarely, normal tissue showed these cells (NHCs), but their transcriptome was easily distinguishable from THCs...
April 8, 2024: Cancers
#9
JOURNAL ARTICLE
Vugar Yagublu, Bayram Bayramov, Christoph Reissfelder, Javahir Hajibabazade, Shalala Abdulrahimli, Michael Keese
Chemotherapy drugs efficiently eradicate rapidly dividing differentiated cells by inducing cell death, but poorly target slowly dividing cells, including cancer stem cells and dormant cancer cells, in the later course of treatment. Prolonged exposure to chemotherapy results in a decrease in the proportion of apoptotic cells in the tumour mass. To investigate and characterize the molecular basis of this phenomenon, microarray-based expression analysis was performed to compare tHcred2 -DEVD-EGFP-caspase 3-sensor transfected C-26 tumour cells that were harvested after engraftment into mice treated with or without 5-FU...
April 12, 2024: Clinical & Experimental Metastasis
#10
JOURNAL ARTICLE
Xiaoyun Li, Yining Xiang, Yunhuan Zhen, Yong Yu
Carrilizumab, a PD-1 inhibitor, has shown therapeutic effectiveness in patients with late-stage or metastatic solid tumors exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). dMMR/MSI-H cancer patients are known to be responsive to PD-1 inhibitors. However, the use of carrilizumab for preoperative immunotherapy in early, unresectable MSI-H/dMMR primary colon cancer lesions is relatively underexplored. We present the case of a 46-year-old male who sought medical attention at our institution due to a history of hematochezia for two weeks, right-sided abdominal pain for one week, and loose stools...
April 11, 2024: Zeitschrift Für Gastroenterologie
#11
JOURNAL ARTICLE
Elysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, Max Nobis, Sharissa L Latham, Amelia L Parker, Kendelle J Murphy, Kaitlin Wyllie, Gretel S Major, Osvaldo Contreras, Ellie T Y Mok, Ronaldo F Enriquez, Suzanne McGowan, Kristen Feher, Lake-Ee Quek, Sarah E Hancock, Michelle Yam, Emmi Tran, Yordanos F I Setargew, Joanna N Skhinas, Jessica L Chitty, Monica Phimmachanh, Jeremy Z R Han, Antonia L Cadell, Michael Papanicolaou, Hadi Mahmodi, Beata Kiedik, Simon Junankar, Samuel E Ross, Natasha Lam, Rhiannon Coulson, Jessica Yang, Anaiis Zaratzian, Andrew M Da Silva, Michael Tayao, Ian L Chin, Aurélie Cazet, Maya Kansara, Davendra Segara, Andrew Parker, Andrew J Hoy, Richard P Harvey, Ozren Bogdanovic, Paul Timpson, David R Croucher, Elgene Lim, Alexander Swarbrick, Jeff Holst, Nigel Turner, Yu Suk Choi, Irina V Kabakova, Andrew Philp, Thomas R Cox
In recent decades, the role of tumor biomechanics on cancer cell behavior at the primary site has been increasingly appreciated. However, the effect of primary tumor biomechanics on the latter stages of the metastatic cascade, such as metastatic seeding of secondary sites and outgrowth remains underappreciated. This work sought to address this in the context of triple negative breast cancer (TNBC), a cancer type known to aggressively disseminate at all stages of disease progression. Using mechanically tuneable model systems, mimicking the range of stiffness's typically found within breast tumors, it is found that, contrary to expectations, cancer cells exposed to softer microenvironments are more able to colonize secondary tissues...
April 11, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
#12
JOURNAL ARTICLE
Davide Ciardiello, Erika Martinelli, Teresa Troiani, Gianluca Mauri, Daniele Rossini, Giulia Martini, Stefania Napolitano, Vincenzo Famiglietti, Sara Del Tufo, Gianluca Masi, Daniele Santini, Antonio Avallone, Filippo Pietrantonio, Sara Lonardi, Massimo Di Maio, Maria Giulia Zampino, Nicola Fazio, Alberto Bardelli, Salvatore Siena, Chiara Cremolini, Andrea Sartore-Bianchi, Fortunato Ciardiello
IMPORTANCE: The available evidence regarding anti-epidermal growth factor receptor (EGFR) inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) is derived from small retrospective and prospective studies. OBJECTIVE: To evaluate the efficacy of anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt mCRC. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial used a pooled analysis of individual patient data from patients with RAS/BRAF wt ctDNA mCRC enrolled in 4 Italian trials (CAVE, VELO, CRICKET, and CHRONOS) and treated with anti-EGFR rechallenge between 2015 and 2022 (median [IQR] follow-up, 28...
April 1, 2024: JAMA Network Open
#13
JOURNAL ARTICLE
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D Danenberg, Narikazu Boku, Takako Eguchi Nakajima
BACKGROUND: Long-term anti-EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single-arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FOLFIRI based on early tumor shrinkage (ETS) in patients with RAS wild-type metastatic colorectal cancer (mCRC). METHODS: Radiologic assessment was performed to evaluate ETS, defined as ≥20% reduction in the sum of the largest diameters of target lesions 8 weeks after the introduction of FOLFIRI plus cetuximab...
April 2024: Cancer Medicine
#14
JOURNAL ARTICLE
Ming-Cheng Chen, Hema Sri Devi, Hsueh-Fa Pien, Shina Fong-Mei Wen, Jenn-Line Sheu, Bruce Chi-Kang Tsai, Chih-Yang Huang, Yu-Jung Lin
Colorectal cancer (CRC) ranks as the third leading cause of cancer-related mortality worldwide. The current standard of care includes systemic chemotherapy with cytotoxic agents, offering palliative relief for severe CRC cases and serving as the primary therapy for metastatic recurrence. However, the development of chemoresistance poses a substantial obstacle in the realm of chemotherapy. This study delved into the potential of a novel chromium (III)-based compound, hexaacetotetraaquadihydroxochromium (III) diiron (III) nitrate, for CRC treatment...
2024: American Journal of Cancer Research
#15
Y Zhan, B Burkel, E J Leaman, S M Ponik, B Behkam
Bacteria-based cancer therapy (BBCT) strains grow selectively in primary tumors and metastases, colonize solid tumors independent of genetics, and kill cells resistant to standard molecular therapy. Clinical trials of BBCT in solid tumors have not reported any survival advantage yet, partly due to the limited bacterial colonization. Collagen, abundant in primary and metastatic solid tumors, has a well-known role in hindering intratumoral penetration of therapeutics. Nevertheless, the effect of collagen content on the intratumoral penetration and antitumor efficacy of BBCT is rarely unexplored...
March 30, 2024: bioRxiv
#16
REVIEW
Mohammad Yasin Zamanian, Maryam Golmohammadi, Bekhzod Abdullaev, María Olalla García, Adeeb Abdulally Abdulhussien Alazbjee, Abhinav Kumar, Sameer S Mohaamed, Beneen M Hussien, Fattaneh Khalaj, Seyede Mahsa Hodaei, Niyousha Shirsalimi, Gervason Moriasi
Colorectal cancer (CRC) is a common and highly metastatic cancer affecting people worldwide. Drug resistance and unwanted side effects are some of the limitations of current treatments for CRC. Naringenin (NAR) is a naturally occurring compound found in abundance in various citrus fruits such as oranges, grapefruits, and tomatoes. It possesses a diverse range of pharmacological and biological properties that are beneficial for human health. Numerous studies have highlighted its antioxidant, anticancer, and anti-inflammatory activities, making it a subject of interest in scientific research...
April 2024: Cell Biochemistry and Function
#17
JOURNAL ARTICLE
Vasudeva Bhat, Matthew Piaseczny, David Goodale, Urvi Patel, Ashkan Sadri, Alison L Allan
Patients with triple-negative breast cancer (TNBC) have an increased propensity to develop lung metastasis. Our previous studies demonstrated that stem-like ALDHhi CD44+ breast cancer cells interact with lung-derived soluble factors, resulting in enhanced migration and lung metastasis particularly in TNBC models. We have also observed that the presence of a primary TNBC tumor can 'prime' the lung microenvironment in preparation for metastasis. In this study, we hypothesized that soluble lung-derived factors secreted in the presence of a primary TNBC tumor can influence stemness/plasticity of breast cancer cells...
April 6, 2024: Clinical & Experimental Metastasis
#18
JOURNAL ARTICLE
Lijun Ma, Fangfang Ai, Hongyan Xiao, Fang Wang, Lei Shi, Xuehong Bai, Yongzhao Zhu, Wenping Ma
Objective: Here, we aimed to explore the effect of LBP in combination with Oxaliplatin (OXA) on reversing drug resistance in colon cancer cells through in vitro and in vivo experiments. We also aimed to explore the possible mechanism underlying this effect. Finally, we aimed to determine potential targets of Lycium barbarum polysaccharide (LBP) in colon cancer (CC) through network pharmacology and molecular docking. Methods: The invasion ability of colon cancer cells was assessed using the invasion assay. The migration ability of these cells was assessed using the migration assay and wound healing assay...
2024: Frontiers in Pharmacology
#19
JOURNAL ARTICLE
Cheng-Yen Wu, Jia-Yo Yu, Yi-Shan Chen, Hui-Ping Chang, Benjamin Y Hsieh, Yu-Hsin Lin, Chung-Yung Ma, Shang-Feng Tsai, Mingli Hsieh
Carbonic anhydrase 8 (CA8) is a member of the α-carbonic anhydrase family but does not catalyze the reversible hydration of carbon dioxide. In the present study, we examined the effects of CA8 on two human colon cancer cell lines, SW480 and SW620, by suppressing CA8 expression through shRNA knockdown. Our results showed that knockdown of CA8 decreased cell growth and cell mobility in SW620 cells, but not in SW480 cells. In addition, downregulated CA8 resulted in a significant decrease of glucose uptake in both SW480 and SW620 cells...
April 2024: Cell Biochemistry and Function
#20
JOURNAL ARTICLE
Salah Eddine El Herrag, Soraya Moulessehoul, Douniazad El Mehadji, Djamila Yekrou, Méghit Boumediène Khaled
OBJECTIVES: The incidence of colorectal cancer (CRC) has exhibited regional variability in North Africa and the Middle East, with a steady increase in Algeria. Despite this trend, limited data exist on the epidemiology of CRC in northwestern Algeria. Our study aimed to investigate the epidemiological characteristics of CRC in this region. METHODS: We conducted a retrospective study examining 255 confirmed CRC cases through medical records from patients at the Sidi Bel Abbes anti-cancer centre...
2024: Ecancermedicalscience
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
